Skip to main
EIKN

EIKN Stock Forecast & Price Target

EIKN Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 0%
Sell 20%
Strong Sell 0%

Bulls say

Eikon Therapeutics is a clinical stage biotechnology company with a dedicated focus on addressing serious unmet medical needs through the development of important medicines. The company's single operating segment, drug discovery, leverages its proprietary technology and clinical development of its product candidates, which include EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006. With a strong pipeline and a commitment to innovation, the company is well-positioned for future growth and success in the biopharmaceutical industry.

Bears say

Eikon Therapeutics is a late-stage clinical biopharmaceutical company with a single operating segment focusing on drug discovery and clinical development of its product candidates, including EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006. The company's financials for the first quarter showed a net loss of $79.7 million, and with current cash and equivalents expected to fund operations into 2H:27, it is crucial for the company to present positive clinical data for its pipeline assets in order to attain its $7 price target and avoid failure from competitor therapies.

EIKN has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eikon Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eikon Therapeutics Inc (EIKN) Forecast

Analysts have given EIKN a Buy based on their latest research and market trends.

According to 5 analysts, EIKN has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eikon Therapeutics Inc (EIKN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.